Advertisement

U.S. markets open in 4 hours

S&P Futures
6,015.50
+28.50(+0.48%)
Dow Futures
44,688.00
+293.00(+0.66%)
Nasdaq Futures
20,968.25
+118.50(+0.57%)
Russell 2000 Futures
2,442.20
+28.60(+1.18%)
Crude Oil
70.76
-0.48(-0.67%)
Gold
2,670.90
-41.30(-1.52%)

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

43.23

+0.34

(+0.79%)

At close: 04:00PM EST

44.29

+1.06

(+2.45%)

Pre-Market:

05:26AM EST

Trade prices are not sourced from all markets

All

Benzinga
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
On Thursday, the FDA granted accelerated approval to PTC Therapeutics, Inc.’s (NASDAQ:PTCT) gene therapy for AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly administered to the brain. The gene therapy, which will be marketed in the United States with the brand name Kebilidi (eladocagene exuparvovec-tneq), is indicated for the treatment of children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency, including the full spectrum of disease sever
Pharmaceutical Technology
FDA grants accelerated approval for PTC’s AADC deficiency gene therapy
KEBILIDI is delivered via a precise neurosurgical procedure to the putamen of the brain.